Market view
Stock chart
Coverage
Analyses on Compugen (3)
- March 2, 2026March 2, 2026
- Follow-up
Compugen: What Is Really Left in Rilvegostomig After the AstraZeneca Amendment
After the AstraZeneca amendment, Compugen's common shareholders still retain meaningful rilvegostomig economics, but the remaining value is narrower, more partner-dependent, and less transparent in the royalty layer. Part of the value has already been turned into cash, while the…
- Follow-up
Compugen: Earnings Quality and the Gap Between Deferred Revenue, Phase 1, and Cash
Compugen’s 2025 Gilead revenue improved reported earnings, but it did so mainly through the release of deferred revenue tied to Phase 1 progress rather than through fresh cash collected in 2025.
Compugen 2025: Cash Bought Time, Not Proof
Compugen bought itself real time through the AstraZeneca amendment and a much stronger cash position, but 2025 still did not prove an independent operating model or a mature clinical value case.
Same sector
